


Figure S1

Schematic of Tatelo Phase A and B Design




bNAb, broadly neutralizing monoclonal antibodies; SMC, Safety Monitoring Committee, ART, antiretroviral treatment

*Enrollments alternate between Groups

Figure S2

Overall goodness of fit of the final PK models



Observed versus individual predicted concentrations for 10-1074 with the line of unity shown by the dashed line. ($r=0.92$) (Supplemental Figure S2A) Observed versus individual predicted concentrations for VRC01LS with the line of unity shown by the dashed line. ($r=0.96$) (Supplemental Figure S2B). Concentrations following single bNAbs administration are represented by the symbol “+” while concentrations following dual bNAbs administration are shown as “o”.